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A B S T R A C T
Cancers of male genital organs (C60-C63) and in particular, prostate cancer, represent one of the most frequent cancer
groups among males in economically developed countries and growing cancer group in developing countries. The Insti-
tute of Public Health of the Osijek-Baranja County in collaborate with different county institutes provide updated infor-
mation on the cancer occurrence and trends in the Osijek-Baranja County (OBC). The aim of this article is to provide in-
formation on the tendencies relating to this cancer group in the OBC during the period from 2001 to 2009, which will be
the first report on these cancer sites on a county level in Croatia. This article processes data on cancer incidence and mor-
tality, appertaining age distribution, median age at diagnosis and at death, cancer survival and length of stay in hospi-
tal in the OBC. From 2001 to 2009, a total of 891 males were diagnosed with cancers of male genital organs and treated
in either of the two OBC hospitals. These cancers accounted for 6.2% of all registered cancers and for 12.5% of all regis-
tered cancers among males. Overall age-standardized incidence rate was 60.9/100,000 and it growing strongly during
the nine-year period. Although the mortality rate increased too (overall rate was 30.5/100,000), the increase was not as
huge as the one in the rate of incidence. Overall median ages at diagnosis and at death were 67.1 years and 74.6 years,
respectively. The 5-year relative survival rate was estimated to be 53.4%. This report reveals weak reduction in the aver-
age length of stay in hospital per patient in the 9-years period (from 11.8 to 11.3 days) and at the same time, the number
of admissions almost tripled (from 84 to 221), which is a consequence of the same rise in the number of newly registered
cases. During the course of the illness, an average patient was hospitalized 1.6 times and the average length of hospital
care was 11.0 days. All the indicators of the quality of the health care provided to C60-C63 cancer patients in the OBC
suggest that further advancement in raising the level of diagnostics and treatment should and can be expected in order to
reach the corresponding EU standards. An increased incidence and mortality rate from C60-C63 cancers leads to the
conclusion that great efforts should be invested into raising the awareness of the male population over 45 years of age on
the recognition of the first symptoms of this cancer group and on early preventive examination as to decrease the mortal-
ity rate and increase the survival rate and the quality of life of patients suffering from this cancer group.
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dian age at diagnosis, median age at death, age distribution, length of stay in hospital, malignant neoplasms of male
genital organs, C60-C63, C61, prostate cancer, Croatia, Osijek-Baranja County
Introduction
The group of cancers of male genital organs (C60-
C63), particularly prostate cancer (C61), is one of the
most frequent cancer groups among males in economi-
cally developed countries. Its incidence is several times
higher than in developing countries, which is a result of
variations in a disparate set of risk factors and diagnostic
practices. The highest incidence rates have been re-
corded in developed countries of Oceania, Europe and
North America. In contrast, males of African descent
from the Caribbean region are characterized by the high-
est prostate cancer mortality rates in the world1. The in-
cidence and mortality rates are rising in several Asian,
Central and eastern European countries2,3. The well-be-
ing of males with prostate cancer is of high public health
significance and interest. Unfortunately, there are side
effects of different kinds of treatment of prostate cancer
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and these include urinary incontinence, bowel and erec-
tile dysfunction4. From 2005 to 2009, the median age at
diagnosis and at death in from prostate cancer the USA
was 67 and 80 years, respectively, Among all registered
patients, only 0.6% of cases referred to patients under 45
years of age (no cases under 35 years of age) while 2/3 of
prostate cancer patients in the USA were diagnosed be-
tween 55 and 74 years of age. The overall age-adjusted
incidence and mortality rate in males were 154.8/100,000
and 23.6/100,000 in males per year, respectively. The
overall 5-year relative survival rate from this cancer in
18 SEER geographic areas was 99.2% in the period from
2002 to 20085. Within the EU, the prostate cancer age-
-standardized incidence rate was 86.7/100,000 in 2006
and the highest rates are estimated in Ireland (183/
100,000) and the lowest ones Greece (28/100,000)6,7. In
the EU as a whole, the prostate cancer mortality rate
showed a modest decline from the 1990–1994 period to
the 2000–2004 period (from 14.9 to 14.3/100,000, –4% at
all ages and from 5.9 to 5.5/100,000, –7% at age 35–64).
In Western Europe, peak mortality rates were observed
in the 1990s8. A decreasing trend of prostate cancer mor-
tality was observed in France, Germany and the UK in
the last decade of the 20th century whereas rates went up
in Russia, Baltic countries, Poland and other central and
eastern European countries9. In Croatia, it was the third
most common male cancer after lung and colorectal can-
cer. The age standardized rate for prostate cancer was
67.8 in 2006 and mortality rate was 27/100,0006,10. Inter-
pretation of trends in the incidence and survival from
this cancer are complicated by the increasing impact of
prostate-specific antigen (PSA) testing. It is not clear
whether changes in the prostate cancer incidence and
mortality result from earlier diagnosis (PSA testing), im-
proved treatment or some combination of these or other
factors. Older age, race (black), and family history remain
the only well-established risk factors in this view11,12.
General information on the C60-C63 cancer group in
Croatia has so far existed only on the national level while
this information on county levels has been scarce13. Data
on the status of this cancer group in the Osijek-Baranja
County (OBC) have never been published (OBC). There-
fore, this paper is aimed at providing general informa-
tion on malignant neoplasms of male genital organs in
the OBC and on the burdens of the health care system
caused by this cancer. This is the first paper that deals
with this issue on a county level in the Republic of
Croatia.
Materials and Methods
Data source
Although the representativeness of their data might
be challenged, mandatory county hospitals data reports,
county bureaus of statistics and the County Register of
Deaths still represent the only available source of infor-
mation on the profile of cancer in the OBC. All data from
the 2001–2009 period originate from these institutions.
The cohort studied in this article included all people with
cancer who were registered as the patients in one of two
hospitals in the OBC in the time period from 1996 to
2010. Based on these sources, a database of people who
were hospitalized in the area of the OBC for any reason
whatsoever (including cancer) has been generated14,15.
The data on each of the hospitalized patients have been
supplemented with data obtained from the Register of
Deaths.
Data on every person with cancer are accompanied
with their chronological order of illness and hospitaliza-
tion. The database involved all hospitalizations and all
data on ONKO or BSL forms (mandatory statistical pat-
terns for all hospitalized patients in Croatia). The ONKO
form is mandatory statistical reports on every hospital-
ized cancer patients in Croatia. The BSL form is a man-
datory statistical report on every hospitalized person, re-
gardless of the causes of hospitalization. All cancer patients
coming from this area are hospitalized in state-owned
(public) hospitals since there are still the only hospitals
here.
Statistical analysis
The cancers were classified according to the Interna-
tional Statistical Classification of Diseases and Related
Health Problems (ICD-10), codes C60-C63. The cancer
incidence and mortality estimates in the period from
2001 to 2009 were prepared for all cancers based on gen-
der and for age groups 0–19, 20–44, 45–64, 65+ by the
year at cancer diagnosis. Based on the 2001 census, the
analysis covered a total population of 330.506 people in
the OBC. The Croatian National Health Insurance is a
universal health insurance that covers all or almost all
costs (depending on a personal choice of the type of in-
surance) of treatment of Croatia citizens and provides
them with the same chances recovery and health care.
Therefore, this article can be said to comprise the entire
population of cancer patients treated in the OBC.
Descriptive statistics were used for both age and gen-
der. The survival rates denote the outcome up to 5 years
after diagnosis. This applies to cancer patients who were
diagnosed with cancer during the 2001–2005 period. All
survival estimates were age-adjusted on the basis of four
age groups. The analyses were conducted using age-spe-
cific rates, the age-standardization-direct method and
95% confidence intervals (95% CI). The standardized in-
cidence and mortality rates as well as the 95% confidence
intervals were computed for C60-C63 pursuant to the
year at cancer diagnosis. Also, both rates were stratified
according to the year at cancer diagnosis, age and gender.
The median age is the observation ranked in the middle;
that is 50% of patients are diagnosed at an older age and
50% are diagnosed at a younger age compared to the me-
dian. The EU standard population was used in the ana-
lysis16. The length of stay was determined according to
the date of admission and to the date of discharge with
regard to the index admission. The SAS statistical pack-
age (version 9.1, SAS Institute INC., Cary, NC, USA) was
used for the statistical analysis17 and Microsoft® Office
Excel® 2007.
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Results
In terms of the entire C60-C63 cancer group, the me-
dian age at diagnosis (MADg) was 67.1 years (Table 1).
The median age for prostate cancer (C61), the most com-
mon cancer in this group (86.9%), was 71.2 years. There
was slightly decrease trendline in median age (R2=0.029).
The median age at death (MAD) was 74.6 years, which is
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TABLE 1
THE OVERALL MEDIAN AGE AT DIAGNOSIS AND AT DEATH FOR MALIGNANT NEOPLASMS OF MALE GENITAL
ORGANS (C60-C63) IN THE OBC, PERIOD 2001–2009, EU STANDARD POPULATION
Overall median age (in years) at diagnosis
ICD-10 Age group OMA (years) COD(S) Strength Trendline
C60 66.7 y=73.56x–0.09, R²=0.195 Moderate DW
C61 71.2 y=71.50x–0.00, R²=0.029 Barely DW
C62 33.2 y=34.84x–0.02, R²=0.011 Barely DW
C63 54.1 y=52.58x0.042, R²=0.024 Barely UW
C60-C63 67.1 y=67.93x–0.00, R²=0.085 Weak DW
Overall median age (in years) at death
C60 69.4 y=75.04x–0.07, R²=0.199 Moderate DW
C61 76.2 y=74.62x0.011, R²=0.253 Moderate UW
C62 47.8 y=64.30x–0.19, R²=0.534 Strong DW
C63 – – – –
C60-C63 74.6 y=74.64x0.004, R²=0.052 Weak UW
Overall median age (in years) at diagnosis (age groups)
C60 45–64 47.9 y=60.44x–0.05, R²=0.035 Weak DW
65+ 68.7 y=71.28x0.041, R²=0.081 Weak UW
442 C61 45–64 60.6 y=60.76x–0.00, R²=0.072 Weak DW
65+ 73.7 y=73.52x0.002, R²=0.029 Barely UW
C62 0–19 17.4 y=15.27x0.066, R²=0.578 Strong UW
20–44 31.0 y=30.17x0.026, R²=0.117 Weak UW
45–64 51.3 y=54.63x0.018, R²=0.013 Barely UW
65+ 67.2 – N/A –
C63 20–44 38.6 – N/A –
45–64 46.2 y=44.40x0.094, R²=0.408 Moderate UW
65+ 78.3 – N/A –
C60-C63 0–19 17.4 17.38493151 N/A –
20–44 31.6 y=31.02x0.012, R²=0.021 Barely UW
45–64 59.3 y=59.55x–0.00, R²=0.021 Barely DW
65+ 73.7 y=73.47x0.002, R²=0.067 Weak UW
Overall median age (in years) at death (age groups)
C60 45–64 58.0 – N/A –
65+ 74.1 y=72.60x0.015, R²=0.081 Weak UW
C61 45–64 60.7 y=61.19x–0.01, R²=0.057 Weak DW
65+ 77.1 y=76.43x0.006, R²=0.190 Moderate UW
C62 20–44 31.9 y=33.01x–0.02, R²=0.084 Weak DW
45–64 54.6 y=67.99x–0.11, R²=0.876 Very Strong DW
65+ 69.8 – N/A –
C60-C63 20–44 31.9 y=33.01x–0.02, R²=0.084 Weak DW
45–64 59.5 y=61.77x–0.02, R²=0.161 Moderate DW
65+ 76.9 y=76.22x0.007, R²=0.239 Moderate UW
COD(S) – Coefficient of determination (strength), »–« or N/A – no cases or too small number of cases, not available, DW – downward,
UW – upward, OMA – overall median age in period 2001–2009, R2 – relationship
7.5 years later than the appertaining MADg. Patients
with prostate cancer in the observed period dies in older
median age (R2=0.253).
The average annual incidence of cancers of male geni-
tal organs in the whole 9-year study period was 99
cases/year (a total of 891 cases, 6.2% of all registered can-
cers and 12.5% of all registered cancers among males in
the OBC). The overall age-standardized incidence rate
(ASIR) was 60.9/100,000 (using the EU standard popula-
tion, SD±6.1 CI 48.91–72.86). The ASIR of the C60-C63
cancer group increased strongly (R2=0.559), particularly
in the years 2004 and 2005 (Table 2). The changes in the
incidence rates in the entire cancer group of C60-C63 di-
rectly dependent on changes in the rate of prostate can-
cer (C61) because its share is 86.9% (Tables 2 and 3, Fig-
ures 1 and 3). The ASIR moderate increased in all age
groups except for the age group up to 20 years
In the same period, there were average annual of 50
(a total of 446 cases) deaths from cancers of male genital
organs (5.2% of all registered deaths and 8.9% of all reg-
istered deaths among males). While the change in the in-
cidence rate was strong, the increasing change in the
age-standardized mortality rate (ASMR) of C60-C63 can-
cers was moderate (R2=0.402, Table 2, Figure 2). The
overall ASMR was 30.5/100,000 (using the EU standard
population, SD±4.3 CI 21.99–38.92). The share of deaths
from prostate cancer is 95.0%. The ASMR moderate in-
creased only in the age group 65+ years, while it slightly
decreased in the age group 45–64 years (Tables 2, 4 and
5, Figure 4).
The overall 5-year relative survival (after cancer diag-
nosis) from cancer group C60-C63 was estimated to be
53.4% (Table 6, Figure 5). Two most common cancer
sites, the malignant neoplasm of prostate (C61) and the
malignant neoplasm of testis (C62) were followed by the
5-year survival rate of 48.5% and 88.6.8%, respectively.
The results in Tables 7.3 and 8.3 and Figure 6 clearly
indicate that new cases of C60-C63 cancers and deaths
from them mostly referred to patients aged 65+ (71.2%
and 89.2%, respectively). Only 9.0% of new cases were
registered in patients aged 0–44 except for prostate can-
cer (C61, 0.0%). Only 1.3% of deaths were registered
among patients aged 0–44 (Tables 7 and 8).
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Fig 1. The cancer age-standardized incidence rate (ASIR) for C60-
-C63 (selected cancer sites) in the period 2001–2009 in the OBC
per 100,000 inhabitants using the EU standard population. The
upward trendline suggests that a moderate relationships exist for
C60 (malignant neoplasm of penis, R2=0.180) and a strong rela-
tionships exist for C61 (malignant neoplasm of prostate), C62 (ma-
lignant neoplasm of testis) and for whole cancer group C60-C63
(R2=0.544, R2=0.500 and R2=0.560, respectively) (R2>0.48<0.81).
Fig 2. The cancer age-standardized mortality rate (ASMR) for
C60-C63 in the period 2001–2009 in the OBC per 100,000 inhab-
itants using the EU standard population. The rising trendlines
suggests that a moderate relationships exist between the ASMR
and years for cancer site C61 and for whole cancer group C60-
C63 (R2=0.357 and R2=0.400, respectively, R2>0.16<0.49.)
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TABLE 2
HISTORICAL DATA ON THE C60-C63 OVERALL CANCER
AGE-STANDARDIZED INCIDENCE AND MORTALITY NUMBER
AND RATES COVERING THE PERIOD FROM 2001–2009
C60-C63 Incidence rate Mortality rate
Year of data
collection
N ASR N ASR
2001 57 35.0 46 28.3
2002 87 53.6 34 20.9
2003 80 49.2 38 23.4
2004 128 78.6 44 27.1
2005 126 77.6 56 34.5
2006 88 54.1 54 33.1
2007 93 57.3 67 41.2
2008 107 65.8 47 28.9
2009 125 76.9 60 36.9
COD(S) – R2= 0.559 0.402
Trendline UW UW
Overall in period
2001–2009
99 60.9 50 30.5
N – average number of cases per year, ASR – age-standardized
rate (EU), UW – upward, COD(S) – Coefficient of determination
(strength), ASR – age-standardized rate per 100,000 (using the
EU standard population), R2 – relationship
TABLE 3
THE OVRALL AGE-STANDARDIZED INCIDENCE RATE (ASIR) IN THE OBC FOR MALIGNANT NEOPLASMS OF MALE
GENITAL ORGANS (C60-C63) PER 100,000 USING EU STANDARD POPULATION, PERIOD 2001–2009
ICD-10
Overall ASIR,
2001–2009
COD(S) Trendline Strength
C60 1.4 y=0.843x0.279, R²=0.180 UW Moderate
C61 53.0 y=34.71x0.275, R²=0.544 UW Strong
C62 6.2 y=3.338x0.389, R²=0.500 UW Strong
C63 0.3 y=0.992x–0.24, R²=0.573 DW Strong
C60-C63 60.9 y=39.90x0.276, R²=0.560 UW Strong
COD(S) – Coefficient of determination (strength), DW – downward, UW – upward, R2 – relationship
TABLE 4
THE OVERALL AGE-STANDARDIZED MORTALITY RATE (ASMR) IN THE OBC FOR MALIGNANT NEOPLASMS OF MALE
GENITAL ORGANS (C60-C63) PER 100,000 USING EU STANDARD POPULATION, PERIOD 2001–2009
ICD-10
Overall ASMR,
2001–2009
COD(S) Trendline Strength
C60 0.6 y = 0.490x0.509, R² = 0.529 UW Strong
C61 28.9 y = 21.88x0.180, R² = 0.357 UW Moderate
C62 1.0 y = 0.662x0.653, R² = 0.954 UW Very Strong
C60-C63 30.5 y = 22.70x0.192, R² = 0.400 UW Moderate
COD(S) – Coefficient of determination (strength), DW – downward, UW – upward, R2 – relationship
Fig. 3. The cancer age-standardized incidence rate (ASIR) for
cancer group C60-C63 (selected cancer sites) in the period 2001–
2009 in the OBC per 100,000 inhabitants using the EU standard
population. The rising trendline suggest that a strong relation-
ship exists for C61 in age 65+ between ASIR and years, R2=
0.486 (R2>0.48<0.81). For other cancer sites there were moder-
ate upward trendlines.
In the 2001–2009 period, a total of 891 patients were
hospitalized in the OBC due to C60-C63 cancers with the
average number of hospital admissions (NOAH) per pa-
tient of 1.6 times (moderate upward trendline, R2=1.6).
The average length of stay in hospital (LOSH) was 11.0
days (Table 9, Figure 7). The LOSH declined with the
age. Patients aged 45–64 diagnosed from the most com-
mon cancer in this group, prostate cancer (C61), spent
0.6 days more in hospital than patients of the 65+ age
group (11.2 and 10.6 days, respectively) (Tables 9 and
10).
The number of hospital admissions increased contin-
uously for all age groups from 2001 to 2009, except for
the 20–44 age group (Table 11). The increase trendline
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TABLE 5
THE AGE-STANDARDIZED INCIDENCE AND MORTALITY RATES IN RELATION WITH AGE OF THE OBC CANCER PATIENTS OF
MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS (C60-C63) IN THE PERIOD 2001–2009, EU STANDARD POPULATION
Incidence rate Mortality rate
Age 2001–2009 COD(S) Trendline Strength 2001–2009 COD(S) Trendline Strength
0–19 1.3 R²=0.107 UW Moderate 0.0 – – –
20–44 13.9 R²=0.325 UW Moderate 1.1 N/A – –
45–64 42.6 R²=0.394 UW Moderate 10.6 R²=0.001 DW No
65+ 409.2 R²=0.464 UW Moderate 249.2 R²=0.471 UW Moderate
COD(S) – Coefficient of determination (strength), R – Relationship, DW – downward, UW – upward, »–« or N/A – no cases or too small
number of cases, not available
TABLE 6
THE FIVE YEARS RELATIVE SURVIVAL RATES FOR C60-C63 CANCERS IN THE OBC, PERIOD 2001–2005
C60-C63 – % (number of survival cases)
ICD-10 0–19 20–44 45–64 65+ All ages
C60 – – 100.1 (1) 101.0 (2) 71.1 (4) 78.8 (7)
C61 – – – – 67.8 (51) 46.4 (149) 48.5 (200)
C62 100.1 (2) 97.3 (34) 50.5 (5) 106.6 (1) 88.6 (42)
C63 – – 100.1 (1) 101.0 (1) 106.6 (1) 101.3 (3)
C60-C63 100.1 (2) 97.4 (36) 67.0 (59) 47.2 (155) 53.4 (252)
»–« – no cases, 0.0 – no survival cases
Fig. 4. The cancer age-standardized mortality rate (ASMR) for
cancer group C60-C63 (selected cancer sites) in the period 2001–
2009 in the OBC per 100,000 inhabitants using the EU standard
population. The rising trendlines suggest that a strong relation-
ship exists for C61 in age 65+ between ASMR and years, R2=
0.486 (R2>0.48<0.81).
Fig. 5. The age-standardized 5-year relative survival rate for
cancer group C60-C63 in the OBC in the 2001–2005 period. The
rising trendlines suggest that a weak relationship exists between
5-years relative survival rates and years, R2=0.117 (R2>0.04<
0.16) and moderate relationship for cancer site C61 (R2=0.367
(R2>0164<0.48).
were strong in the age groups 45–64 and 65+ years
(R2=0.667 and R2=0.729, respectively). During the who-
le 9-year period, the increase in the hospital admissions
was almost fourfold in the 45–64 age group (from 12 to
54, strong upward trendline R2=0.667) while the hospi-
tal admissions more than doubled in the 65+ age group
(from 56 to 133, strong upward trendline, R2=0.729).
The average LOSH was weakly decreased in the 45–64
age group (R2=0.146), in the 65+ age group (R2=0.110),
but moderately increased in the 20–44 age group (R2=
0.182, Table 11).
Discussion
The rates of cancers of male genital organs (especially
prostate cancer) vary widely throughout the globe. These
cancers are least common in South and East Asia and
more common in Europe and the United States. The inci-
dence rates greatly differentiate worldwide mostly due to
wide utilization of PSA testing18,19. Tendencies in the in-
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TABLE 7
THE AGE DISTRIBUTION AT DIAGNOSIS FOR MALIGNANT
NEOPLASMS OF MALE GENITAL ORGANS (C60–C63) IN THE
OBC, PERIOD 2001–2009
TABLE 7.1
ICD-10 Age 2001–2009 (%) Trendline COD(S)
C60 20–44 5.0 - N/A
45-64 45.0 - N/A
65+ 50.0 UW R2=0.079
C61 45–64 19.5 UW R2=0.052
65+ 80.5 DW R2=0.083
C62 0-19 6.5 UW R2=0.001
20–44 78.3 DW R2=1E-05
45–64 14.1 DW *R2=0.382
65+ 1.1 - N/A
C63 20–44 20.0 - N/A
45–64 60.0 - N/A
65+ 20.0 - N/A
C60–C63 0–19 0.7 - N/A
20–44 8.3 - R2=0.008
45–64 19.8 - R2=0.078
65+ 71.3 - *R2=0.131
TABLE 7.2
C60 All ages 2.2 DW R²=1E–05
C61 86.9 DW R²=2E–05
C62 10.3 UW *R²=0.173
C63 0.6 DW **R²=0.0752
TABLE 7.3 The age proportion of each cancer site
0–44 45–64 65+ All ages
C60 0.1 1.0 1.1 2.2
C61 0.0 16.9 69.9 86.9
C62 8.8 1.5 0.1 10.3
C63 0.1 0.3 0.1 0.6
C60–C63 9.0 19.8 71.2
R – relationship, * – moderate R, ** – strong R, *** – very strong
and extremely dependable R, COD(S) – Coefficient of determi-
nation (strength), N/A – not available, COD(S), DW – down-
ward, UW – upward, »–« – weak or no R, BG – Both genders, F –
Females, M – Males
TABLE 8
THE AGE DISTRIBUTION AT DEATH FOR MALIGNANT
NEOPLASMS OF MALE GENITAL ORGANS (C60–C63) IN THE
OBC, PERIOD 2001–2009
TABLE 8.1
ICD-10 Age 2001–2009 (%) Trendline COD(S)
C60 45–64 44.4 - N/A
65+ 55.6 DW **R2=0.497
C61 45–64 7.6 DW R2=0.154
65+ 92.4 UW *R2=0.200
C62 20–44 42.9 UW **R2=0.649
45–64 42.9 DW R2=0.145
65+ 14.3 – N/A
C60–C63 20–44 1.3 UW ***R2=0.891
45–64 9.4 DW R2=0.058
65+ 89.2 UW R2=0.006
TABLE 8.2
C60 All ages 2.0 UW *R²=0.255
C61 94.9 DW R²=0.048
C62 3.1 UW **R²=0.722
TABLE 8.3 The age proportion of each cancer site
0–44 45–64 65+ All ages
C60 – 0.9 1.1 2.0
C61 – 7.2 87.7 94.9
C62 1.3 1.3 0.4 3.1
C60–C63 1.3 9.4 89.2
R – relationship, * – moderate R, ** – strong R, *** – very strong
and extremely dependable R, COD(S) – Coefficient of determi-
nation (strength), N/A – not available COD(S), DW – downward,
UW – upward, »–« – weak or no R, BG – Both genders, F – Fe-
males, M – Males
Fig. 6. The age distribution for malignant neoplasms of male ge-
nital organs (C60-C63) in the period 2001–2009.
cidence and mortality rate from prostate cancer in Croa-
tia (unlike the trends in Europe) have disclosed an in-
crease since 199720,21. During the 9-year study period
(2001–2009), the incidence (strongly) and mortality rate
(moderately) increased in the OBC. Despite the fact that
the health care in the OBC has been familiar and pro-
vided with all the procedures and knowledge needed for
early detection of these cancers, particularly prostate
cancer (digital rectal examination, PSA and transrectal
ultrasound of the prostate and other methods), it is not
clear why the mortality rate is still growing. A lack of
necessary information and a late visit to the doctor for
preventive examination in males aged 65+ with dis-
turbed prostate functions (e.g. erectile and urinary dys-
function) might be identified as reasons for the rising
mortality in the OBC.
The age-standardized incidence rate of C60-C63 can-
cers in the OBC was lower than those in the EU and
Croatia but is still increasing. It may reflect no recent
stabilization of prostate-specific antigen test utilities, re-
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TABLE 9
THE NUMBER OF CANCER HOSPITALIZATIONS AND THE AVERAGE LENGTH OF STAY IN HOSPITAL FOR MALIGNANT
NEOPLASMS OF MALE GENITAL ORGANS (C60-C63) IN THE OBC, PERIOD 2001–2009
Number of hospital admissions Overall length of stay in hospital
Age groups
ICD-10 0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
C60 – 2 18 21 41 – 8.5 11.2 11.3 11.1
C61 – – 225 951 1176 – – 11.2 10.6 10.7
C62 7 165 31 1 204 21.1 12.4 10.6 4.0 12.4
C63 – 1 3 2 6 – 15.0 12.7 22.5 16.3
C60-C63 21.1 12.4 11.1 10.6 11.0
C60
Overall – 0.2 2.0 2.3 4.6 – 8.5 11.2 11.3 11.1
COD(S) R² = N/A N/A 0.727 0.301 0.000 N/A N/A 0.076 0.113 0.122
Trendline N/A N/A UW DW UW N/A N/A DW UW UW
Strength N/A N/A Strong Moderate Barely N/A N/A Weak Weak Weak
C61
Overall – – 25.0 105.7 130.7 – – 11.2 10.6 10.7
COD(S) R² = N/A N/A 0.631 0.759 0.817 N/A N/A 0.199 0.080 0.212
Trendline N/A N/A UW UW UW N/A N/A DW DW DW
Strength N/A N/A Strong Strong Very Strong N/A N/A Moderate Weak Moderate
C62
Overall 0.8 18.3 3.4 0.1 22.7 21.1 12.4 10.6 4.0 12.4
COD(S) R² = 0.107 0.131 0.398 N/A 0.351 0.035 0.202 0.000 N/A 0.155
Trendline UW UW DW N/A UW UW UW DW N/A UW
Strength Weak Weak Moderate N/A Moderate Weak Moderate Barely N/A Weak
C63
Overall – 0.1 0.3 0.2 0.7 – 15.0 12.7 22.5 16.3
COD(S) R² = N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Trendline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Strength N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
C60-C63
Overall 0.8 18.7 30.8 108.3 158.6 21.1 12.4 11.1 10.6 11.0
COD(S) R² = 0.107 0.106 0.667 0.729 0.800 0.035 0.182 0.146 0.110 0.040
Trendline UW UW UW UW UW UW UW DW DW DW
Strength Weak Weak Strong Strong Strong Weak Moderate Weak Weak Weak
COD(S) – Coefficient of determination (strength), R – Relationship, DW – downward, UW – upward, »–« or N/A – no cases or too small
number of cases, not available, Overall – overall in period 2001–2009
sulting in decreased detection or a reduced number of
timely diagnosed cases. The mortality rate was two times
higher than that in the EU and did not exceed the Cro-
atian average by much6–10. Prostate cancer alone ac-
counted for 12.5% of new cancer cases among males in
the OBC, which is still only a half way to the appertain-
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Fig. 7. Length of stay in hospital (LOSH) (in days) and number of hospital admissions (NOAH) of cancer group C60-C63 in the OBC in
the 2001–2009 period. Very strong and strong relationships exist between NOAH and years for C61 and C60-C63 (R2= 0.817 and
R2=0.800, respectively).
TABLE 10
THE YEARS OF DIAGNOSIS AND TRENDLINES OF THE AVERAGE ADMISSION IN HOSPITAL, THE AVERAGE LENGTH OF STAY IN
HOSPITAL AND THE NUMBER OF ADMISSION IN HOSPITAL PER PATIENT FOR SELECTED MALIGNANT NEOPLASMS OF MALE
GENITAL ORGANS (C60-C63) IN THE OBC, PERIOD 2001–2009
Year
C61 C62 C60-C63
NOAH N AAH LOSH NOAH N AAH LOSH NOAH N AAH LOSH
2001 62 48 1.3 12.9 15 5 3.0 10.0 84 57 1.5 11.8
2002 91 77 1.2 9.4 24 8 3.0 10.6 123 87 1.4 10.3
2003 97 70 1.4 12.6 15 8 1.9 13.3 114 80 1.4 12.8
2004 156 114 1.4 10.1 27 11 2.5 7.9 188 128 1.5 9.6
2005 164 109 1.5 11.0 21 16 1.3 18.2 190 126 1.5 11.9
2006 143 79 1.8 10.3 18 7 2.6 9.6 165 88 1.9 10.2
2007 155 82 1.9 10.2 20 8 2.5 12.1 178 93 1.9 10.5
2008 129 89 1.4 10.8 28 14 2.0 13.7 164 107 1.5 11.1
2009 179 106 1.7 10.4 36 15 2.4 15.0 221 125 1.8 11.3
2001–2009 1176 774 1.5 10.7 204 92 2.2 12.4 1427 891 1.6 11.0
COD(S) – R2 = 0.817 0.543 0.558 0.212 0.351 0.491 0.153 0.155 0.800 0.559 0.404 0.040
Trendline UW UW UW DW UW UW UW UW UW UW UW DW
NOAH – number of hospital admissions, N – number of cases, AAH – average admission in hospital per patient, LOSH – length of stay
in hospital, COD(S) – Coefficient of determination (strength), UW – upward, DW – downward
ing USA percentage (28%). However, the 5-year relative
survival rate approaches 100% in the latter country
nowadays22. The mean European 5-year relative survival
was 76.5%. In Nordic countries, the survival rate was
generally above the European mean while in Eastern
countries, it was systemically lower, which supports the
thesis about great differences in C60-C63 cancer survival
rates across Europe23. Unfortunately, the OBC 5-year
relative survival rate of 53.4% from the C60-C63 cancer
group and 48.5% from prostate cancer (C61) were both
much below the European average. At this point, these
discouraging data are difficult to explain. On the one
hand, it is well known the way in which diagnosis and
treatment is carried out. These activities are known to
medical professionals and the manner in which they are
implemented. On the other hand, it is declared that these
activities are implemented. What is then the reason for
these data?
The risk of getting C60-C63 cancers and prostate can-
cer alone rose rapidly with the age in the OBC. All pa-
tients who died of prostate cancer were at least 45 years
old at the moment of death.
The length of stay in hospital is as an important fac-
tor influencing both hospital charges and patient costs.
This report reveals a weak decline in the length of stay in
hospital per patient in period 2001–2009 while at the
same time, the number of admissions and average admis-
sion in hospital per patient strongly went up. Implemen-
tation of clinical pathways for patients with prostate can-
cer has been confirmed as a simple and effective method
for reducing length of hospital stay without having effect
on complications, readmission rates or patient satisfa-
ction24. The question which length of hospitalization is
optimal and necessary after implementation of this pro-
cedure arises controversies25. Unfortunately, mandatory
statistical reports (ONKO forms) in the OBC (as well as
on the state level) did not contain information on imple-
mented medical treatments, so there is no possibility to
compare the length of hospitalization with them. It is a
pity that this problem has existed in Croatia for years.
All the indicators of the quality of the health care pro-
vided to C60-C63 cancer patients in the OBC26,27 suggest
that further advancement in raising the level of timely
diagnostics and treatment of the OBC patients should
and can be expected in order to reach the corresponding
European standards. An increased incidence and mortal-
ity rate from C60-C63 cancers leads to the conclusion
that great efforts should be invested into raising the
awareness of the male population over 45 years of age on
the recognition of the first symptoms of this cancer
group and on necessary regular examination as to pre-
vent fatal consequences therefrom. Finally, the 5-year
relative survival rate from this cancer is below the Cro-
atian average, which is a worrying fact that directly ad-
dresses the health care system.
Limitations
Patients who were treated outside the two state-
-owned (public) hospitals in the OBC are not registered
with the IPHO. Despite the efforts to obtain this infor-
mation (it exists at the national level) in its original
form, the authors were unable to obtain those data for
unknown reasons. Therefore, these data on cancer in the
OBC may differ from the official state data on cancer in
the OBC.
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TABLE 11
THE YEARS OF DIAGNOSIS AND THE AVERAGE LENGTH OF STAY IN HOSPITAL (LOSH) AND NUMBER OF HOSPITAL ADMISSIONS
(NOHA) FOR MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS (C60-C63) IN THE OBC, PERIOD 2001–2009
Year
NOAH Average LOSH
0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
2001 – 16 12 56 84 – 10.3 12.2 12.1 11.8
2002 – 15 27 81 123 – 9.2 13.1 9.6 10.3
2003 1 14 19 80 114 10.0 13.6 10.5 13.2 12.8
2004 – 25 33 130 188 – 8.3 10.6 9.7 9.6
2005 1 15 39 135 190 52.0 18.1 11.9 10.9 11.9
2006 – 11 30 124 165 – 11.8 10.0 10.1 10.2
2007 4 13 24 137 178 17.5 10.2 13.8 9.7 10.5
2008 – 26 39 99 164 – 13.0 10.7 10.8 11.1
2009 1 33 54 133 221 16.0 15.5 9.6 10.9 11.3
Trendline UW UW UW UW UW 21.1 UW DW DW DW
COD (S) – R2 = 0.107 0.106 0.667 0.729 0.800 0.035 0.182 0.146 0.110 0.040
2001–2009 0.8 18.7 30.8 108.3 158.6 21.1 12.4 11.1 10.6 11.0
Strength Weak Weak Strong Strong Strong Weak Moderate Weak Weak Weak
COD (S) – R2 – Coefficient of determination (strength), R – relationship, »–« – downward trendline, »+« – upward trendline, NOAH –
number of hospital admissions, LOSH – length of stay in hospital, »–« – no cases
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RAK MU[KIH SPOLNIH ORGANA U OSJE^KO-BARANJSKOJ @UPANIJI, HRVATSKA
S A @ E T A K
Rak mu{kih spolnih organa (C60-C63), te posebno rak prostate kao najzna~ajniji rak ove skupine, je jedan od naj~e{-
}ih karcinoma u mu{karaca u razvijenim zemljama i s intenzivnim rastom broja oboljelih u zemljama u razvoju. Zavod
za javno zdravstvo Osje~ko-baranjske `upanije u suradnji s razli~itim `upanijskim institucijama obra|uje podatke veza-
ne za pojavu i kretanje raka na podru~ju Osje~ko-baranjske `upanije (OBC). Cilj ovoga ~lanka je dati informaciju o
kretanju raka mu{kih spolnih organa u OBC u vremenu od 2001–2009 godine kao prvi ovakav izvje{taj na razini jedne
`upanije u Hrvatskoj. ^lanak sadr`i podatke o incidenciji i smrtnosti, dobnoj raspodjeli, srednjoj dobi, pre`ivljavanju i
du`ini hospitalizacije oboljelih od raka ove skupine. U devetogodi{njem periodu obolio je 891 pacijent od raka mu{kih
spolnih organa. Oni ~ine 6,2% udjela u ukupnom raku u OBC, odnosno 12.5% udjela u raku mu{karaca. Dobno stan-
dardizirana stopa novooboljelih je 60,9/100.000 i raste tijekom promatranog vremena. Premda stopa smrtnosti tako|er
raste (prosje~na stopa je 30,5/100.000), taj porast nije niti pribli`no sna`an kao {to je porast stope novooboljelih. Za
cijelu skupinu raka C60-C63 srednja dob u trenutku postavljanja dijagnoze je bila 67,1 godina, odnosno 74,6 godina za
umrle. Petogodi{nje relativno pre`ivljavanje je 53,4%. Tijekom promatranog razdoblja neznatno se smanjila prosje~na
du`ina hospitalizacije (od 11.8 na 11,3 dana), a u istom vremenu je gotovo trostruko porastao broj prijema u bolnicu (od
84 u 2001. godini na 221 prijema u 2006. godini) {to je izravna posljedica pove}anja broja novooboljelih. Oboljeli su
prosje~no 1,6 puta bili hospitalizirani zbog raka s prosje~nom du`inom boravka u bolnici od 11,0 dana. Svi pokazatelji o
zdravstvenoj za{titi bolesnika oboljelih od C60-C63 ukazuju da se u zdravstvu OBC treba i mo`e o~ekivati daljnji napre-
dak u podizanju pravodobne dijagnostike i lije~enja oboljelih stanovnika `upanije kako bi se dohvatili EU rezultati i
standardi. Pove}anje incidencije i smrtnosti od C60-C63 grupe raka upu}uje da zajednica u OBC treba ulo`iti napore
kako bi se u mu{koj populaciji starijoj od 45 godina podigla svijest o prepoznavanju prvih simptoma raka ove skupine i
ranim preventivnim pregledom djelovalo na posljedice raka. Tako|er zabrinjava podatak o lo{ijem pre`ivljavanju nakon
postavljene dijagnoze raka nego {to je ono u EU, a to se izravno odnosi na zdravstveni sustav.
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